Tachyon Therapeutics, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $7.1 million grant to support a Phase I clinical study of TACH101 in patients with advanced solid tumors.
[Tachyon Therapeutics, Inc.]